25 results about "Eclampsia preeclampsia" patented technology

The invention discloses a construction method and application of a preeclampsia animal model based on an RASA3 target, and belongs to the technical field of biomedicine.The preeclampsia animal model is constructed by injecting Ad-RASA3 into a pregnant mouse and monitoring pathological indexes, related to preeclampsia, of the pregnant mouse. According to the method, the animal model with preeclampsia-like clinical symptoms can be stably induced, the abnormal change of the uterine spiral artery remodeling process can be systematically monitored, the method is high in operation controllability and model stability, and an effective tool can be provided for deeply researching the pathogenesis of preeclampsia and developing a novel diagnosis and treatment strategy.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention discloses an application of TMEM106A as a target spot in preparation of a diagnostic kit and a targeted therapeutic drug. Relates to the technical field of immunodiagnosis. Specific applications are provided. The invention discloses a key effect of TMEM106A in podocyte injury related to preeclampsia. TMEM106A is significantly down-regulated in urine of a PE patient, is closely related to podocyte injury and inflammatory response, and can be used as an early noninvasive diagnostic marker; meanwhile, the targeted podocyte up-regulation TMEM106A has remarkable anti-inflammatory and kidney protection effects, and a theoretical basis and practical feasibility are provided for targeted therapy of PE-related podocyte injury. The invention provides a new way for early precise diagnosis and intervention strategy of PE, and has wide clinical application prospect.

This invention relates to a group of genes associated with gestational hypertension, a method for predicting gestational hypertension in early pregnancy using these genes, and related applications. Specifically, this invention obtains transcript start site feature values ​​from at least one of the following genes from the cfDNA sample of a pregnant woman: LOC124902572, EEF1A1P16, LOC105369767, GOLM2, CDRT7, MEIS3, and LOC105376108. These transcript start site feature values ​​are then input into a prediction model, and the output results are used to determine the risk of gestational hypertension. The number of sequences in the transcript start site region after correction based on the transcript start site feature values ​​is also considered. The prediction model obtained by this invention can effectively and robustly predict the risk of gestational hypertension (including preeclampsia) in early pregnancy, assisting doctors in early pregnancy intervention and reducing the risk of gestational hypertension.

The application provides application of FABP4 in preparation of a preeclampsia diagnosis product and a preeclampsia treatment drug, belongs to the technical field of biotechnology, and in particular, the application provides application of a FABP4 detection reagent in preparation of a preeclampsia diagnosis product and application of a FABP4 inhibitor in preparation of a preeclampsia treatment drug, and the application proves for the first time that FABP4 can be used as a preeclampsia diagnosis marker and proves that FABP4 can be directly used as a treatment target of preeclampsia, provides a diagnosis and treatment target for diagnosis and treatment of preeclampsia, lays a solid foundation for development of a preeclampsia treatment drug, and opens up a new way for precise treatment of preeclampsia.

This invention belongs to the field of pharmaceutical application technology, specifically relating to a folic acid derivative, its preparation method, and its application in preventing and treating ferroptosis. The folic acid derivative of this invention comprises compounds represented by general formula (I) and their pharmaceutically acceptable salts. The folic acid compounds provided by this invention, by introducing a lipophilic group or a specific group at the R position, yield compounds with good ferroptosis inhibitory activity, which can be used to treat non-alcoholic steatohepatitis, acute liver injury, cardiomyopathy, drug-induced cardiotoxicity, atherosclerosis, acute kidney injury, renal fibrosis, pneumonia, preeclampsia, osteoporosis, osteoarthritis, traumatic brain injury, and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and epilepsy.

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 antibody and an anti-sEng antibody bound to a solid support in order to reduce blood levels of sFlt-1 and sEng. The present disclosure relates to methods, systems, devices, and apparatuses for treating pregnancy-related hypertensive disorders such as pre-eclampsia and eclampsia.

The invention discloses a diagnostic marker for preeclampsia, relates to the technical field of biological medicines, and comprises application of a reagent for detecting PDCD5 in preparation of a diagnostic tool for preeclampsia. Experiments prove that the PDCD5 gene and the expression product thereof are differentially expressed in normal placenta tissue and peripheral blood as well as preeclampsia placenta tissue and peripheral blood, so that the PDCD5 gene and the expression product thereof can be used as biomarkers for diagnosing preeclampsia.

The invention discloses a preeclampsia piRNA noninvasive diagnostic marker, a diagnostic kit and application, and belongs to the technical field of molecular biology, the marker is piR-002094, and the nucleotide sequence of the marker is shown as SEQ ID NO: 1. The marker disclosed by the invention can be applied to preparation of kits and preparation of therapeutic drugs of the kits. The kit comprises a specific primer and a standardized reagent, and can be used for sensitively detecting the expression (AUC = 0.779) of piR-002094 in plasma. The piR-002094 inhibitor (SEQ ID NO: 7) provides a new strategy for preeclampsia treatment by inhibiting the piR-002094 to reduce the secretion of IL-6 (Interleukin-6).

The invention is applicable to the technical field of biological medicine, and provides application of a traditional Chinese medicine monomer in preparation of a medicine for treating preeclampsia, the traditional Chinese medicine monomer is rhynchophylline, and the rhynchophylline is clear in source, high in safety and pure in structure. Retrieval shows that no research report or patent disclosure for the rhynchophylline for preeclampsia treatment exists at present, and no systematic evaluation of the rhynchophylline under a multi-model system exists. According to the invention, a multi-model system is constructed for the first time, the intervention effect of the rhynchophylline on the preeclampsia is systematically evaluated, and the situation that the rhynchophylline can remarkably improve gestational hypertension, reduce the urine protein level and repair placenta structure and functional damage is found, so that effective intervention on the preeclampsia is realized. The invention fills the technical blank in the field, has a good application prospect, and provides a safe and controllable natural active ingredient and an application scheme thereof for preeclampsia.

Disclosed in the present invention is the use of a water extract of Amomi fructus and / or a vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia. Further disclosed in the present invention is the use of the water extract of Amomi fructus and / or the vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia, or a drug for preventing and / or treating proteinuria caused by preeclampsia, or a drug for reversing a reduction in placental weight caused by preeclampsia, or a drug for restoring fetal intrauterine growth restrictions caused by preeclampsia, or a drug for restoring pathological damage to placental tissue or placental dysfunction caused by preeclampsia, or a drug for reversing the reduction in placental efficiency caused by preeclampsia, or a drug for repairing colonic barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching the intestinal tract of a patient with preeclampsia with Bifidobacterium bifidum. The present invention overcomes the limitations of current drugs for treating preeclampsia which exhibit limited single therapeutic effects and gastrointestinal adverse reactions.

The invention discloses an application of an immune costimulatory factor TNFSF9 / TNFRSF9 as a marker in preparation of a preeclampsia intervention product, and the immune costimulatory factor as an intervention target comprises TNFSF9 and / or TNFRSF9. According to the application, activation and immune response of immune cells of the placenta are accurately regulated and controlled by targeting a TNFSF9 / TNFRSF9 signal channel (signal axis), so that immune system disorder is effectively improved, local and systemic inflammatory response is relieved, the immune homeostasis of the placenta is recovered, and the pathophysiological process of preeclampsia is relieved.

The application discloses a serine nano-drug for treating preeclampsia by targeting placental oxidative stress, which can pass through the placental barrier by changing the particle size, thereby increasing the local concentration of serine in the placenta to achieve the purpose of relieving placental oxidative stress and treating preeclampsia. The placental barrier is the barrier between the placental villus tissue and the uterine blood sinus, and is an important basis for maintaining normal pregnancy. However, the placental barrier also hinders the entry of drugs into the placenta, affecting the treatment effect of drugs on placental diseases, such as preeclampsia, fetal intrauterine growth restriction and the like. The nano-drug is prepared by using nano-preparation technology to make raw drugs into particles with a nano scale, and has the advantage of penetrating through the body barrier. The amino acid involved in oxidative stress regulation, serine, is synthesized into nano-serine by using nano technology, so that serine can pass through the placental barrier by changing the particle size of nano-serine, thereby increasing the local concentration of serine in the placenta, and achieving the purpose of treating preeclampsia by reducing placental oxidative stress.

The invention relates to an evaluation model and method for predicting a neonatal bad outcome based on antenatal examination. The main outcome of the neonatal adverse outcome comprises two parts of disease diagnosis and invasive treatment, and the neonatal adverse outcome is related to death and long-term health risk of children. The evaluation model comprises evaluation variables of weight gain during pregnancy, preeclampsia, umbilical artery S / D, congenital malformation and SGA, wherein the preeclampsia, the congenital malformation and the SGA are independent risk factors of neonatal adverse outcome. According to the scoring method, scoring is carried out based on the evaluation model, when at least one item of preeclampsia, congenital malformation, SGA and maternal congenital heart disease is' YES ', a neonatal adverse outcome high-risk group is prompted, and the higher the score is, the higher the probability of occurrence of the neonatal adverse outcome is. According to the invention, medical professionals can be rapidly helped to more effectively predict the neonatal adverse outcome, so that clinical decision-making is promoted.

The present application relates to the field of medical data analysis, and more particularly to a method for dynamically predicting the risk of pre-eclampsia premature birth based on monitoring indicators during pregnancy, which comprises: obtaining an individual measured time series set and a basic time weighted average feature; obtaining a recent transient decompensation momentum factor by performing recent deterioration dynamics analysis on monitoring data near the current evaluation time; obtaining a steady-state fracture and barrier breakdown factor by jointly evaluating the evolution trend and fluctuation potential of the historical monitoring sequence; obtaining a reconstructed fusion feature vector by fusing and reconstructing the basic time weighted average feature and the steady-state fracture and barrier breakdown factor; and obtaining a dynamic prediction result of the risk of premature birth by inputting the reconstructed fusion feature vector into a Cox proportional hazards model for risk prediction, thereby solving the problem that the existing prediction method based on time weighted average and linear feature fusion cannot effectively identify recent decompensation deterioration signals and maternal-fetal state deviation risks.

The application discloses an application of an agonist of a cAMP-activated exchange protein in preparation of a drug for treating preeclampsia, and belongs to the technical field of biological medicines, wherein the drug is used for treating preeclampsia by activating a Rap1 signal pathway of human aortic smooth muscle cells inhibited by a RASA3 protein, and the agonist of the cAMP-activated exchange protein is 8-CPT-2'-O-Me-cAMP or a pharmaceutically acceptable salt or solvent mixture thereof. The application proves for the first time that the compound has a function of promoting migration and remodeling in vascular smooth muscle cells, and successfully applies the compound to the treatment of preeclampsia, a pregnancy-related vascular disease, thereby expanding a new use of the compound in the field of clinical treatment of preeclampsia.

The invention discloses a PAPPA2-171aa protein and an application of the PAPPA2-171aa protein. The amino acid sequence of the PAPPA2-171aa protein is as shown in SEQ ID NO: 1. The PAPPA2-171aa protein which can be used for inhibiting invasion and migration of trophoblast cells is obtained through screening, through overexpression of the PAPPA2-171aa, it is found that the invasion and migration capacities of the trophoblast cells are obviously inhibited, it is indicated that the PAPPA2-171aa protein can participate in regulation and control of occurrence and development of preeclampsia, the PAPPA2-171aa protein can be used for screening drugs for treating preeclampsia, and the PAPPA2-171aa protein can be used for preparing drugs for treating preeclampsia. And a new research direction is provided for developing a medicine for treating preeclampsia.

Methods of detecting pre-term pre-eclampsia in specific sub-cohorts of pregnant women are described. The methods employ metabolite biomarkers and ratios of metabolite biomarkers. Systems for early calculation of risk of pre-term pre-eclampsia in specific sub-cohorts of pregnant women are also described.

The invention relates to a method for screening and predicting a lipid biomarker for preeclampsia based on wide targeting lipidomics. The method comprises the following steps: (1) pre-treating a sample; (2) carrying out targeted lipidomics detection; (3) qualitative and quantitative analysis of lipid markers; and (4) screening of differential lipid markers. According to the invention, lipid metabolism markers such as DAG (16: 1 / 18: 1) and the like are screened through the method, and clinical research support is expected to be provided for clinical exploration of pathogenesis of preeclampsia.

The present invention refers to an in vitro method for the determination of the risk of a subject suffering of preeclampsia as well as computer implemented methods thereof.

Disclosed herein are methods and systems for determining risk of preeclampsia. The system can include (a) a computer comprising: (i) a processor; and (II) a memory, coupled to the processor, the memory storing a module comprising: (1) test data for a sample from a subject including values indicating a quantitative measure of one or more markers; (2) a classification rule which, based on values including the measurements, classifies the subject as being at risk of preeclampsia, wherein the classification rule is configured to have a sensitivity of at least 75%, at least 85% or at least 95%; and (3) computer executable instructions for implementing the classification rule on the test data.

The invention discloses a preeclampsia marker as well as application and a kit thereof. Comprising phosphatase and tension protein (PTEN), and the marker can be used for preparing a serological detection preeclampsia diagnostic reagent or diagnostic tool to perform early screening on preeclampsia risk population and fill the blank of current preeclampsia serological diagnosis. The invention belongs to the technical field of medicine. Furthermore, the invention also provides an ELISA kit for detecting preeclampsia, the sampling means is non-invasive and non-invasive, high-precision endoscope equipment is not needed, the kit can be applied to primary medical institutions, the early diagnosis of preeclampsia and the adoption of prevention means for intervention are facilitated, and the kit has good application value.

The present invention is directed to the use of the heparin derivative tafoxiparin in the treatment of preeclampsia (PE). The treatment may be monotherapy or combination therapy, where tafoxiparin is used in combination with an agent (drug) used as standard of care therapy in preeclampsia (PE).

The application discloses an application of a tRNA-derived small fragment RNA 5-CysGCA-L15 mimic in preparation of a drug for preventing or treating preeclampsia, wherein an unmodified base sequence of the 5-CysGCA-L15 mimic is the same as that of natural 5-CysGCA-L15, and the natural 5-CysGCA-L15 nucleotide sequence is shown as SEQ ID NO:1; the mimic is prepared by introducing chemical modification for enhancing nucleic acid stability and / or cell uptake efficiency at one or more sites of the nucleotide sequence shown as SEQ ID NO:1; and the application discloses a potential regulation role of 5-CysGCA-L15 in occurrence and development of preeclampsia, wherein the constructed mimic can promote trophoblast proliferation, migration and invasion, improve placental dysfunction and placental development related abnormalities, and improve related pathological phenotypes in a preeclampsia animal model.